BIDAC Trademark

Trademark Overview

On Monday, July 13, 2020, a trademark application was filed for BIDAC with the United States Patent and Trademark Office. The USPTO has given the BIDAC trademark a serial number of 90049788. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, December 14, 2021. This trademark is owned by C4 Therapeutics, Inc.. The BIDAC trademark is filed in the Pharmaceutical Products category with the following description:

Protein degraders for the prevention and treatment of human diseases and conditions, namely, cancer, tumors, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, viral diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, enzyme deficiency diseases and disorders, and infectious diseases; pharmaceutical products for the prevention and treatment of cancer, tumors, autoimmune disorders, neurological, vascular and infectious diseases; pharmaceutical preparations for immunotherapy
bidac

General Information

Serial Number90049788
Word MarkBIDAC
Filing DateMonday, July 13, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, December 14, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesProtein degraders for the prevention and treatment of human diseases and conditions, namely, cancer, tumors, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, viral diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, enzyme deficiency diseases and disorders, and infectious diseases; pharmaceutical products for the prevention and treatment of cancer, tumors, autoimmune disorders, neurological, vascular and infectious diseases; pharmaceutical preparations for immunotherapy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 12, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameC4 Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Trademark Events

Event DateEvent Description
Tuesday, December 14, 2021ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, December 14, 2021ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, June 2, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 2, 2021NON-FINAL ACTION E-MAILED
Wednesday, June 2, 2021NON-FINAL ACTION WRITTEN
Friday, April 23, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 23, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 23, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, October 24, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, October 24, 2020NON-FINAL ACTION E-MAILED
Saturday, October 24, 2020NON-FINAL ACTION WRITTEN
Thursday, October 22, 2020ASSIGNED TO EXAMINER
Wednesday, August 12, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

bidac diseases disorders infectious tumors autoimmune neurological cancer pharmaceutical treatment prevention